Compass Pathways publishes results of psilocybin treatment in anorexia nervosa

COMPASS Pathways announced the publication of a paper in Nature Medicine that demonstrates the potential for COMP360 psilocybin treatment in anorexia nervosa. The investigator-initiated open-label study was conducted by Drs. Walter Kaye and Stephanie Knatz Peck at the University of California San Diego School of Medicine and is believed to be the first clinical research study to report the effects of psilocybin treatment in anorexia nervosa. The study investigated the safety, efficacy, and tolerability of a single 25mg dose of COMP360 psilocybin, with psychological support, in female patients with anorexia nervosa. The results showed: 40% of participants experienced clinically significant reductions in eating disorder psychopathology at the three-month follow-up. Participants demonstrated statistically significant reductions from baseline in shape concerns at the one-month follow-up, and weight concerns at the three-month follow-up. Changes in eating concern were approaching significance at three-month follow-up. Five participants demonstrated an increase in body mass index at three-month follow-up. Changes in BMI were not statistically significant. Overall, the psilocybin experience was regarded as meaningful by participants. Ninety percent endorsed feeling more positive about life endeavors; 80% endorsed the experience as one of the top five most meaningful of their life; and 70% reported experiencing a shift in personal identity and overall quality of life. COMP360 psilocybin treatment was well tolerated. All adverse events were mild and transient in nature. No serious adverse events were reported.